Valneva (VALN) Competitors $6.92 +0.16 (+2.37%) As of 04/2/2025 03:17 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VALN vs. BEAM, VCEL, MIRM, GMTX, EWTX, CNTA, KYMR, CGON, DNLI, and BLTEShould you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Beam Therapeutics (BEAM), Vericel (VCEL), Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), Edgewise Therapeutics (EWTX), Centessa Pharmaceuticals (CNTA), Kymera Therapeutics (KYMR), CG Oncology (CGON), Denali Therapeutics (DNLI), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. Valneva vs. Beam Therapeutics Vericel Mirum Pharmaceuticals Gemini Therapeutics Edgewise Therapeutics Centessa Pharmaceuticals Kymera Therapeutics CG Oncology Denali Therapeutics Belite Bio Valneva (NASDAQ:VALN) and Beam Therapeutics (NASDAQ:BEAM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, community ranking, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Which has more volatility and risk, VALN or BEAM? Valneva has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Do institutionals and insiders believe in VALN or BEAM? 11.4% of Valneva shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 4.2% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is VALN or BEAM more profitable? Valneva has a net margin of -4.35% compared to Beam Therapeutics' net margin of -41.07%. Valneva's return on equity of -3.93% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Valneva-4.35% -3.93% -1.42% Beam Therapeutics -41.07%-16.22%-10.94% Does the MarketBeat Community prefer VALN or BEAM? Beam Therapeutics received 26 more outperform votes than Valneva when rated by MarketBeat users. However, 65.00% of users gave Valneva an outperform vote while only 58.56% of users gave Beam Therapeutics an outperform vote. CompanyUnderperformOutperformValnevaOutperform Votes3965.00% Underperform Votes2135.00% Beam TherapeuticsOutperform Votes6558.56% Underperform Votes4641.44% Do analysts prefer VALN or BEAM? Valneva presently has a consensus price target of $16.00, indicating a potential upside of 131.21%. Beam Therapeutics has a consensus price target of $49.45, indicating a potential upside of 167.61%. Given Beam Therapeutics' higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, VALN or BEAM? Valneva has higher revenue and earnings than Beam Therapeutics. Valneva is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioValneva$169.58M3.32-$109.78M-$0.17-40.71Beam Therapeutics$63.52M29.03-$132.53M-$4.58-4.03 Does the media refer more to VALN or BEAM? In the previous week, Beam Therapeutics had 4 more articles in the media than Valneva. MarketBeat recorded 17 mentions for Beam Therapeutics and 13 mentions for Valneva. Valneva's average media sentiment score of 0.44 beat Beam Therapeutics' score of 0.20 indicating that Valneva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 4 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryValneva beats Beam Therapeutics on 10 of the 18 factors compared between the two stocks. Remove Ads Get Valneva News Delivered to You Automatically Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VALN vs. The Competition Export to ExcelMetricValnevaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$562.33M$2.97B$5.58B$7.92BDividend YieldN/A1.53%5.35%4.04%P/E Ratio-53.2330.8023.1118.81Price / Sales3.32404.50368.7688.86Price / CashN/A168.6838.1634.64Price / Book3.463.696.684.18Net Income-$109.78M-$72.06M$3.20B$247.10M7 Day Performance-4.55%-6.90%-3.93%-2.72%1 Month Performance1.47%-13.30%1.68%-3.90%1 Year Performance-11.51%-28.40%8.24%-0.11% Valneva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VALNValneva1.8854 of 5 stars$6.92+2.4%$16.00+131.2%-8.5%$562.33M$169.58M-53.23700Analyst ForecastBEAMBeam Therapeutics3.234 of 5 stars$24.01+3.0%$50.82+111.7%-39.5%$2.40B$63.52M-13.64510Short Interest ↑Gap DownVCELVericel3.3338 of 5 stars$47.94+3.6%$62.29+29.9%-13.6%$2.40B$237.22M799.13300Positive NewsMIRMMirum Pharmaceuticals4.4016 of 5 stars$47.02flat$58.20+23.8%+78.5%$2.30B$336.89M-23.28140GMTXGemini TherapeuticsN/A$52.24-1.9%N/A+37.8%$2.26BN/A-52.2430High Trading VolumeEWTXEdgewise Therapeutics2.1902 of 5 stars$23.37-1.0%$45.38+94.2%-12.2%$2.22BN/A-15.5860Analyst ForecastOptions VolumeNews CoverageGap DownCNTACentessa Pharmaceuticals2.9361 of 5 stars$16.63+5.6%$26.00+56.3%+20.9%$2.19B$6.85M-10.87200Analyst ForecastAnalyst RevisionKYMRKymera Therapeutics1.3572 of 5 stars$33.70+3.6%$56.36+67.2%-30.0%$2.19B$47.07M-14.40170News CoverageCGONCG Oncology1.1816 of 5 stars$28.53+5.5%$63.88+123.9%-45.1%$2.17B$684,000.000.0061Analyst ForecastAnalyst RevisionNews CoverageDNLIDenali Therapeutics4.3781 of 5 stars$14.76+2.3%$37.20+152.0%-29.1%$2.14B$330.53M-5.35430News CoverageBLTEBelite Bio2.2246 of 5 stars$66.94-0.5%$96.33+43.9%+71.3%$2.13BN/A-60.3110 Remove Ads Related Companies and Tools Related Companies BEAM Alternatives VCEL Alternatives MIRM Alternatives GMTX Alternatives EWTX Alternatives CNTA Alternatives KYMR Alternatives CGON Alternatives DNLI Alternatives BLTE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VALN) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
